Product Focus Target expansion opportunities around Zilretta and other local musculoskeletal therapies for osteoarthritis, emphasizing narrative around non-opioid, extended-release injections that align with current opioid-sparing and pain-management trends.

Strategic Buyer Identify potential acquirers or partners in large pharma with interest in neuromusculoskeletal franchises, leveraging Flexion’s Zilretta asset and the recent acquisition activity (e.g., Pacira) to frame a compelling value proposition for licensing or acquisition discussions.

Clinical & Payer Alignment Develop value-based discussions with payers and clinicians by highlighting extended-release benefits, reduced opioid use, and updated commercial metrics, aiming to position Zilretta as a cost-effective option for knee OA pain management.

territory & Partnerships Map potential regional or specialty-care partnerships, including orthopedics, rheumatology, and sports medicine networks, plus anti-inflammatory and analgesic collaborations that could broaden adoption and co-promotion opportunities.

Financial & Growth Signals Leverage Flexion’s mid-market revenue range and recent funding signals to craft scalable, milestone-driven deals, while preparing for conversations with potential suitors about pipeline acceleration and commercialization support.